- Home
- WGRX vs ACET Comparison
WGRX vs ACET Comparison
Compare WGRX & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WGRX | ACET |
|---|---|---|
| Founded | 2022 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.2M | 71.3M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | WGRX | ACET |
|---|---|---|
| Price | $0.39 | $8.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $96.67 |
| AVG Volume (30 Days) | ★ 381.6K | 230.6K |
| Earning Date | 02-11-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $34,077,635.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 495.93 | N/A |
| 52 Week Low | $0.34 | $7.15 |
| 52 Week High | $7.04 | $17.44 |
Technical Indicators
Market Signals| Indicator | WGRX | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 37.15 | 85.72 |
| Support Level | $0.35 | $7.94 |
| Resistance Level | $0.44 | $8.55 |
| Average True Range (ATR) | 0.04 | 0.35 |
| MACD | 0.00 | 0.60 |
| Stochastic Oscillator | 33.97 | 88.24 |
Price Performance
Historical ComparisonAbout WGRX Wellgistics Health Inc.
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. It is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.